Fried Frank acted as counsel to Catalent in connection with the issuance of US$500 million aggregate principal amount of 5% senior notes due 2027. The net proceeds were used to repay in full the outstanding borrowings under Catalent's US dollar-denominated term loans that mature in May 2024 under its senior secured credit facilities, plus any accrued and unpaid interest thereon, pay related fees and expenses, and provide cash for general corporate purposes. Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer and animal health products.
The Fried Frank team was led by corporate partners Daniel J. Bursky and Joshua Thomas Coleman and included tax partner Michael J. Alter; corporate associates Danica E. Curavic, Nicholas R. Luciano, and Charles Stern; and tax associates Ryan L. Conley and Thomas A. Mitchell.